Monoclonal Antibody to Extracellular Signal Regulated Kinase 2 (ERK2)
| Code | Size | Price |
|---|
| MAA930Hu21-20ul | 20uL | £99.00 |
Quantity:
| MAA930Hu21-100ul | 100ul | £191.00 |
Quantity:
| MAA930Hu21-200ul | 200ul | £260.00 |
Quantity:
| MAA930Hu21-1ml | 1ml | £603.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1 Kappa
Antibody Clonality: Monoclonal
Antibody Clone: D17
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
MAPK1; P38; P40; ERK2; ERT1; MAPK2; P42MAPK; P42-MAPK; PRKM1; PRKM2; P41; P41mapk; P41-mapk; Mitogen-Activated Protein Kinase 1; Mitogen-activated protein kinase 2
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Extracellular Signal Regulated Kinase 2
Potency (Clone Number):
D17
Reactivity:
Mu;Ra;Po;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.2-2ug/mL;
<br/>Optimal working dilutions must be determined by end user.
<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Extracellular Signal Regulated Kinase 2 (ERK2) | RPA930Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||